BioNTech has agreed to buy another specialist in mRNA-based vaccines and therapeutics, fellow German biotech CureVac, in an all-stock deal valued at around $1.25 billion.

The future of the genetic data owned by 23andMe is uncertain as the company undergoes a court-supervised sale.

A company like 23andMe can answer a lot of questions for an adoptee. But those answers come with a high cost to privacy.

Maine and 27 other states are suing 23andMe to stop the bankrupt DNA-test firm from selling customers’ genetic data.

Lawmakers want to know what will be done to make sure consumer genetic testing company 23andMe’s data will stay out of the ...

GREENVILLE, S.C. (FOX Carolina/AP) - South Carolina is one of 27 states to join a lawsuit to block the sale of 23andMe users’ ...

During a hearing on the privacy implications of 23andMe selling its business, its interim CEO says 1.9 million people, or ...

Twenty-seven states and the District of Columbia have sued the bankrupt genetic testing company 23andMe in an effort to block ...

Multiple states and the District Columbia are pushing back on bankrupt 23andMe’s plans to sell customer genetic information ...

People did not submit their personal data to 23andMe thinking their genetic blueprint would later be sold off to the highest ...

Regeneron founder, chairman and CEO Dr. Leonard Schleifer joins 'Squawk Box' to discuss the company's bid for 23andMe, ...

Dozens of states, including New York, are suing to block the sale of 23andMe personal genetic data without customer consent.